Consumer Study for the Evaluation of the Usability and Efficacy of One Medical Device in Venous Return

NCT ID: NCT06153680

Last Updated: 2023-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-10

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to assess in vivo the efficacy of the insoles in improving venous return in subjects affected by this problem after 14 days of medical device use, by self-assessment, filling-in questions regarding Quality of Life, in comparison to the baseline.

The secondary goals of this study are (1) to assess in vivo the perception of subjects about the rapid relief felt after 7 days of using the same medical device, by self-assessment, filling-in three subjective evaluation questions, and (2) to assess in vivo the usability of the subjects regarding the same medical device after 14 days of its use, by self-assessment, filling-in subjective evaluation questions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Disease Quality of Life Symptoms and Signs

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic venous disease, insoles, quality of life, symptoms, relief,

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

One medical device as investigational device

Group Type EXPERIMENTAL

Insoles

Intervention Type DEVICE

Device : Insoles

At Day 0, the patient received the insoles and adapted them to his shoes.

The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.

The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Insoles

Device : Insoles

At Day 0, the patient received the insoles and adapted them to his shoes.

The patient filled the quality-of-life's questionnaire at Day 0 and the same at Day14.

The patient filled the rapid relief's questionnaire at Day7 and a usability's questionnaire at Day14.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gender: Female/Male;
* Age: with 18 years old and older;
* Having signed an Informed Consent Form (ICF);
* Willingness, ability and likeliness to comply with all the study procedures and restrictions;
* Ability to give informed consent;
* Available during the entire study period;
* Understanding Portuguese language: Portuguese-speaking subjects capable of reading the documents;
* Affected by a symptomatic venous return problem;

Exclusion Criteria

* Known allergy or known history of hypersensitivity to the components of the investigational device and related compounds;
* Currently participating in another clinical study that may interfere with the study;
* Diagnosed skin diseases and/or cutaneous alterations on the test region (feet) that may impair the study (for example tattoos, marks, burns, scars, etc.);
* Diagnosed diseases that may impair the study (including but not limited to: Diabetes, Arteritis, Phlebitis, etc);
* Under pharmacological treatments on the 30 days previous to the beginning of the study and during the entire period of the study that may impair it (including but not limited to: inflammatory drugs, any drug that might cover the signs and symptoms, drugs with arterial or venous indications, etc.);
* Having applied any type of topical product (pharmaceutical, cosmetic or other) with similar effect of the medical device under study, on the test region (feet) during the study, besides the investigational device;
* Having a stage of CVD C3 on the CEAP classification;
* Having had a traumatic or neurological history in the last 6 months;
* Wearing an orthopaedic insole made by a health professional;
* Having a significant and disabling lower limb pain;
* Having a significant and disabling back pain;
* Having a contraindication to wearing insoles;
* Pregnancy or intention to conceive during the study;
* Breast-feeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Millet Innovation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marta de Oliveira Ferreira

Role: PRINCIPAL_INVESTIGATOR

INOVAPOTEK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inovapotek

Porto, , Portugal

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Portugal

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P115B22

Identifier Type: -

Identifier Source: org_study_id